Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Germ Cell Tumors

Robert A. Huddart

罗伯特·哈达特

MA, MBBS, PhD, FRCR

🏢The Royal Marsden NHS Foundation Trust / Institute of Cancer Research(皇家马斯顿NHS基金会信托医院/癌症研究所)🌐UK

Professor of Urological Cancer; Consultant Clinical Oncologist泌尿癌症学教授;临床肿瘤顾问医师

44
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Prominent UK clinical oncologist at the Royal Marsden specializing in testicular cancer radiotherapy, chemotherapy, and survivorship. Led pivotal MRC and UK-based GCT trials and the TE23 carboplatin vs. radiotherapy studies. Expert in cardiovascular and second cancer risks in GCT survivors.

Share:

🧪Research Fields 研究领域

Germ Cell Tumors生殖细胞肿瘤
Testicular Cancer睾丸癌
Cancer Survivorship癌症生存者研究

🎓Key Contributions 主要贡献

Seminoma Radiotherapy and Carboplatin Trials

Led MRC TE19 and TE23 trials comparing carboplatin vs. radiotherapy for stage I seminoma and para-aortic vs. dog-leg radiotherapy fields, directly shaping modern treatment standards.

GCT Survivorship and Late Effects

Conducted large UK survivorship cohort studies documenting elevated cardiovascular disease, second malignancy, and metabolic risks in long-term testicular cancer survivors.

Cardiovascular Risk in GCT Survivors

Demonstrated significantly increased myocardial infarction risk following cisplatin and mediastinal radiation, informing survivorship monitoring and lifestyle intervention programs.

Representative Works 代表性著作

[1]

Carboplatin Versus Radiotherapy for Stage I Seminoma (MRC TE19)

Journal of Clinical Oncology (2011)

Long-term follow-up confirming single-dose carboplatin equivalent to radiotherapy in relapse prevention for stage I seminoma with similar late toxicity profiles.

[2]

Cardiovascular Disease Risk in Survivors of Testicular Cancer

Journal of Clinical Oncology (2003)

Large UK cohort study demonstrating doubled myocardial infarction risk in men treated with cisplatin or radiotherapy for testicular cancer.

[3]

Second Cancers After Testicular Cancer Treatment

British Journal of Cancer (2012)

Comprehensive analysis of second malignancy risk in UK testicular cancer survivors, informing long-term surveillance recommendations.

🏆Awards & Recognition 奖项与荣誉

🏆Royal College of Radiologists Fellowship
🏆British Uro-oncology Group Distinguished Lecturer
🏆Institute of Cancer Research Translational Research Prize

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 罗伯特·哈达特 的研究动态

Follow Robert A. Huddart's research updates

留下邮箱,当我们发布与 Robert A. Huddart(The Royal Marsden NHS Foundation Trust / Institute of Cancer Research)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment